Ken Griffin Sab Biotherapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.62 - $1.0 $10,365 - $16,719
16,719 New
16,719 $11,000
Q1 2023

May 15, 2023
SELL
$0.42 - $0.75 $33,942 - $60,611
-80,815 Reduced 74.0%
28,400 $12,000
Q4 2022

Feb 14, 2023
BUY
$0.54 - $9.8 $37,288 - $676,719
69,053 Added 171.94%
109,215 $64,000
Q3 2022

Nov 14, 2022
BUY
$0.13 - $12.4 $5,221 - $498,008
40,162 New
40,162 $28,000

Others Institutions Holding SABS

# of Institutions
3
Shares Held
529K
Call Options Held
0
Put Options Held
0
View Full List

About SAB Biotherapeutics, Inc.

SABS Quotes by TradingView
  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $111M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email